The global market for Neurological Disorder Drugs was valued at US$ 2298 million in the year 2024 and is projected to reach a revised size of US$ 4087 million by 2031, growing at a CAGR of 8.7% during the forecast period.

Neurological Disorder Drugs Market

Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.

Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.

This report aims to provide a comprehensive presentation of the global market for Neurological Disorder Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurological Disorder Drugs.

The Neurological Disorder Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurological Disorder Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neurological Disorder Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neurological Disorder Drugs Market Report

Report Metric	Details
Report Name	Neurological Disorder Drugs Market
Accounted market size in year	US$ 2298 million
Forecasted market size in 2031	US$ 4087 million
CAGR	8.7%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Antipsychotic Hypnotic & Sedative Analgesics Anticoagulants Others
Segment by Application	Hospital Clinic
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, GlaxoSmithKline, Merck & Co., Bayer, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurological Disorder Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Neurological Disorder Drugs Market growing?

Ans: The Neurological Disorder Drugs Market witnessing a CAGR of 8.7% during the forecast period 2025-2031.

What is the Neurological Disorder Drugs Market size in 2031?

Ans: The Neurological Disorder Drugs Market size in 2031 will be US$ 4087 million.

Who are the main players in the Neurological Disorder Drugs Market report?

Ans: The main players in the Neurological Disorder Drugs Market are Novartis, GlaxoSmithKline, Merck & Co., Bayer, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical

What are the Application segmentation covered in the Neurological Disorder Drugs Market report?

Ans: The Applications covered in the Neurological Disorder Drugs Market report are Hospital, Clinic

What are the Type segmentation covered in the Neurological Disorder Drugs Market report?

Ans: The Types covered in the Neurological Disorder Drugs Market report are Antipsychotic, Hypnotic & Sedative, Analgesics, Anticoagulants, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Antipsychotic

1.2.3 Hypnotic & Sedative

1.2.4 Analgesics

1.2.5 Anticoagulants

1.2.6 Others

1.3 Market by Application

1.3.1 Global Neurological Disorder Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neurological Disorder Drugs Market Perspective (2020-2031)

2.2 Global Neurological Disorder Drugs Growth Trends by Region

2.2.1 Global Neurological Disorder Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Neurological Disorder Drugs Historic Market Size by Region (2020-2025)

2.2.3 Neurological Disorder Drugs Forecasted Market Size by Region (2026-2031)

2.3 Neurological Disorder Drugs Market Dynamics

2.3.1 Neurological Disorder Drugs Industry Trends

2.3.2 Neurological Disorder Drugs Market Drivers

2.3.3 Neurological Disorder Drugs Market Challenges

2.3.4 Neurological Disorder Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neurological Disorder Drugs Players by Revenue

3.1.1 Global Top Neurological Disorder Drugs Players by Revenue (2020-2025)

3.1.2 Global Neurological Disorder Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Neurological Disorder Drugs Revenue

3.4 Global Neurological Disorder Drugs Market Concentration Ratio

3.4.1 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neurological Disorder Drugs Revenue in 2024

3.5 Global Key Players of Neurological Disorder Drugs Head office and Area Served

3.6 Global Key Players of Neurological Disorder Drugs, Product and Application

3.7 Global Key Players of Neurological Disorder Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Neurological Disorder Drugs Breakdown Data by Type

4.1 Global Neurological Disorder Drugs Historic Market Size by Type (2020-2025)

4.2 Global Neurological Disorder Drugs Forecasted Market Size by Type (2026-2031)

5 Neurological Disorder Drugs Breakdown Data by Application

5.1 Global Neurological Disorder Drugs Historic Market Size by Application (2020-2025)

5.2 Global Neurological Disorder Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Neurological Disorder Drugs Market Size (2020-2031)

6.2 North America Neurological Disorder Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Neurological Disorder Drugs Market Size by Country (2020-2025)

6.4 North America Neurological Disorder Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neurological Disorder Drugs Market Size (2020-2031)

7.2 Europe Neurological Disorder Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Neurological Disorder Drugs Market Size by Country (2020-2025)

7.4 Europe Neurological Disorder Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neurological Disorder Drugs Market Size (2020-2031)

8.2 Asia-Pacific Neurological Disorder Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Neurological Disorder Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Neurological Disorder Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neurological Disorder Drugs Market Size (2020-2031)

9.2 Latin America Neurological Disorder Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Neurological Disorder Drugs Market Size by Country (2020-2025)

9.4 Latin America Neurological Disorder Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neurological Disorder Drugs Market Size (2020-2031)

10.2 Middle East & Africa Neurological Disorder Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Neurological Disorder Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Neurological Disorder Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Neurological Disorder Drugs Introduction

11.1.4 Novartis Revenue in Neurological Disorder Drugs Business (2020-2025)

11.1.5 Novartis Recent Development

11.2 GlaxoSmithKline

11.2.1 GlaxoSmithKline Company Details

11.2.2 GlaxoSmithKline Business Overview

11.2.3 GlaxoSmithKline Neurological Disorder Drugs Introduction

11.2.4 GlaxoSmithKline Revenue in Neurological Disorder Drugs Business (2020-2025)

11.2.5 GlaxoSmithKline Recent Development

11.3 Merck & Co.

11.3.1 Merck & Co. Company Details

11.3.2 Merck & Co. Business Overview

11.3.3 Merck & Co. Neurological Disorder Drugs Introduction

11.3.4 Merck & Co. Revenue in Neurological Disorder Drugs Business (2020-2025)

11.3.5 Merck & Co. Recent Development

11.4 Bayer

11.4.1 Bayer Company Details

11.4.2 Bayer Business Overview

11.4.3 Bayer Neurological Disorder Drugs Introduction

11.4.4 Bayer Revenue in Neurological Disorder Drugs Business (2020-2025)

11.4.5 Bayer Recent Development

11.5 AstraZeneca

11.5.1 AstraZeneca Company Details

11.5.2 AstraZeneca Business Overview

11.5.3 AstraZeneca Neurological Disorder Drugs Introduction

11.5.4 AstraZeneca Revenue in Neurological Disorder Drugs Business (2020-2025)

11.5.5 AstraZeneca Recent Development

11.6 Boehringer Ingelheim

11.6.1 Boehringer Ingelheim Company Details

11.6.2 Boehringer Ingelheim Business Overview

11.6.3 Boehringer Ingelheim Neurological Disorder Drugs Introduction

11.6.4 Boehringer Ingelheim Revenue in Neurological Disorder Drugs Business (2020-2025)

11.6.5 Boehringer Ingelheim Recent Development

11.7 Teva Pharmaceutical

11.7.1 Teva Pharmaceutical Company Details

11.7.2 Teva Pharmaceutical Business Overview

11.7.3 Teva Pharmaceutical Neurological Disorder Drugs Introduction

11.7.4 Teva Pharmaceutical Revenue in Neurological Disorder Drugs Business (2020-2025)

11.7.5 Teva Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Neurological Disorder Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Antipsychotic

Table 3. Key Players of Hypnotic & Sedative

Table 4. Key Players of Analgesics

Table 5. Key Players of Anticoagulants

Table 6. Key Players of Others

Table 7. Global Neurological Disorder Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Neurological Disorder Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Neurological Disorder Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Neurological Disorder Drugs Market Share by Region (2020-2025)

Table 11. Global Neurological Disorder Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Neurological Disorder Drugs Market Share by Region (2026-2031)

Table 13. Neurological Disorder Drugs Market Trends

Table 14. Neurological Disorder Drugs Market Drivers

Table 15. Neurological Disorder Drugs Market Challenges

Table 16. Neurological Disorder Drugs Market Restraints

Table 17. Global Neurological Disorder Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Neurological Disorder Drugs Market Share by Players (2020-2025)

Table 19. Global Top Neurological Disorder Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Disorder Drugs as of 2024)

Table 20. Ranking of Global Top Neurological Disorder Drugs Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Neurological Disorder Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Neurological Disorder Drugs, Headquarters and Area Served

Table 23. Global Key Players of Neurological Disorder Drugs, Product and Application

Table 24. Global Key Players of Neurological Disorder Drugs, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Neurological Disorder Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Neurological Disorder Drugs Revenue Market Share by Type (2020-2025)

Table 28. Global Neurological Disorder Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Neurological Disorder Drugs Revenue Market Share by Type (2026-2031)

Table 30. Global Neurological Disorder Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Neurological Disorder Drugs Revenue Market Share by Application (2020-2025)

Table 32. Global Neurological Disorder Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Neurological Disorder Drugs Revenue Market Share by Application (2026-2031)

Table 34. North America Neurological Disorder Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Neurological Disorder Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Neurological Disorder Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Neurological Disorder Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Neurological Disorder Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Neurological Disorder Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Neurological Disorder Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Neurological Disorder Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Neurological Disorder Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Neurological Disorder Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Neurological Disorder Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Neurological Disorder Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Neurological Disorder Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Neurological Disorder Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Neurological Disorder Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 49. Novartis Company Details

Table 50. Novartis Business Overview

Table 51. Novartis Neurological Disorder Drugs Product

Table 52. Novartis Revenue in Neurological Disorder Drugs Business (2020-2025) & (US$ Million)

Table 53. Novartis Recent Development

Table 54. GlaxoSmithKline Company Details

Table 55. GlaxoSmithKline Business Overview

Table 56. GlaxoSmithKline Neurological Disorder Drugs Product

Table 57. GlaxoSmithKline Revenue in Neurological Disorder Drugs Business (2020-2025) & (US$ Million)

Table 58. GlaxoSmithKline Recent Development

Table 59. Merck & Co. Company Details

Table 60. Merck & Co. Business Overview

Table 61. Merck & Co. Neurological Disorder Drugs Product

Table 62. Merck & Co. Revenue in Neurological Disorder Drugs Business (2020-2025) & (US$ Million)

Table 63. Merck & Co. Recent Development

Table 64. Bayer Company Details

Table 65. Bayer Business Overview

Table 66. Bayer Neurological Disorder Drugs Product

Table 67. Bayer Revenue in Neurological Disorder Drugs Business (2020-2025) & (US$ Million)

Table 68. Bayer Recent Development

Table 69. AstraZeneca Company Details

Table 70. AstraZeneca Business Overview

Table 71. AstraZeneca Neurological Disorder Drugs Product

Table 72. AstraZeneca Revenue in Neurological Disorder Drugs Business (2020-2025) & (US$ Million)

Table 73. AstraZeneca Recent Development

Table 74. Boehringer Ingelheim Company Details

Table 75. Boehringer Ingelheim Business Overview

Table 76. Boehringer Ingelheim Neurological Disorder Drugs Product

Table 77. Boehringer Ingelheim Revenue in Neurological Disorder Drugs Business (2020-2025) & (US$ Million)

Table 78. Boehringer Ingelheim Recent Development

Table 79. Teva Pharmaceutical Company Details

Table 80. Teva Pharmaceutical Business Overview

Table 81. Teva Pharmaceutical Neurological Disorder Drugs Product

Table 82. Teva Pharmaceutical Revenue in Neurological Disorder Drugs Business (2020-2025) & (US$ Million)

Table 83. Teva Pharmaceutical Recent Development

Table 84. Research Programs/Design for This Report

Table 85. Key Data Information from Secondary Sources

Table 86. Key Data Information from Primary Sources

Table 87. Authors List of This Report

List of Figures

Figure 1. Neurological Disorder Drugs Picture

Figure 2. Global Neurological Disorder Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Neurological Disorder Drugs Market Share by Type: 2024 VS 2031

Figure 4. Antipsychotic Features

Figure 5. Hypnotic & Sedative Features

Figure 6. Analgesics Features

Figure 7. Anticoagulants Features

Figure 8. Others Features

Figure 9. Global Neurological Disorder Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Neurological Disorder Drugs Market Share by Application: 2024 VS 2031

Figure 11. Hospital Case Studies

Figure 12. Clinic Case Studies

Figure 13. Neurological Disorder Drugs Report Years Considered

Figure 14. Global Neurological Disorder Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Neurological Disorder Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Neurological Disorder Drugs Market Share by Region: 2024 VS 2031

Figure 17. Global Neurological Disorder Drugs Market Share by Players in 2024

Figure 18. Global Top Neurological Disorder Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Disorder Drugs as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Neurological Disorder Drugs Revenue in 2024

Figure 20. North America Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Neurological Disorder Drugs Market Share by Country (2020-2031)

Figure 22. United States Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Neurological Disorder Drugs Market Share by Country (2020-2031)

Figure 26. Germany Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Neurological Disorder Drugs Market Share by Region (2020-2031)

Figure 34. China Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Neurological Disorder Drugs Market Share by Country (2020-2031)

Figure 42. Mexico Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Neurological Disorder Drugs Market Share by Country (2020-2031)

Figure 46. Turkey Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Neurological Disorder Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Novartis Revenue Growth Rate in Neurological Disorder Drugs Business (2020-2025)

Figure 50. GlaxoSmithKline Revenue Growth Rate in Neurological Disorder Drugs Business (2020-2025)

Figure 51. Merck & Co. Revenue Growth Rate in Neurological Disorder Drugs Business (2020-2025)

Figure 52. Bayer Revenue Growth Rate in Neurological Disorder Drugs Business (2020-2025)

Figure 53. AstraZeneca Revenue Growth Rate in Neurological Disorder Drugs Business (2020-2025)

Figure 54. Boehringer Ingelheim Revenue Growth Rate in Neurological Disorder Drugs Business (2020-2025)

Figure 55. Teva Pharmaceutical Revenue Growth Rate in Neurological Disorder Drugs Business (2020-2025)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

Figure 58. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-4R20263

Sat Nov 22 00:00:00 UTC 2025

Add to Cart

Global Online Speech Therapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-39V19943

Sat Nov 22 00:00:00 UTC 2025

Add to Cart

Global Nerve Repair and Regeneration Devices Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-10C17235

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Neurological Disease Model Chip Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-7M17348

Thu Nov 06 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Neurological Disorder Drugs Market Research Report 2025

Published Date: August 2025

Report Code: QYRE-Auto-19X9811

Global Neurological Disorder Drugs Market Research Report 2025

FEATURED COMPANIES

Neurological Disorder Drugs Market Size

Neurological Disorder Drugs Market

Scope of Neurological Disorder Drugs Market Report

Chapter Outline

FAQ for this report

How fast is Neurological Disorder Drugs Market growing?

What is the Neurological Disorder Drugs Market size in 2031?

Who are the main players in the Neurological Disorder Drugs Market report?

What are the Application segmentation covered in the Neurological Disorder Drugs Market report?

What are the Type segmentation covered in the Neurological Disorder Drugs Market report?

FEATURED COMPANIES

RELATED REPORTS